The manufacturer of tazemetostat has now formally begun its planned Phase 2 clinical trial of this novel targeted mesothelioma therapeutic. Tazemetostat is reported to be capable of inhibiting EZH2 activity. Epizyme, Inc., based in Cambridge, Massachusetts, announced in mid-August 2016 that the first of an expected 67 patients began receiving tazemetostat. Tazemetostat is designed to
Monthly Archives: August 2016
Your doctor has some good advice for you. Never stop taking your mesothelioma medicines. You want to live long? Then keep taking those medicines. Yet many mesothelioma patients do just the opposite. They stop taking their medicines. Or they get lazy and take them only occasionally. Or they simply forget. This has a name. It’s
Consider yourself fortunate if you don’t have mesothelioma despite exposure to asbestos at some point in your past. But your good fortune might not hold if you currently have Crohn’s disease. Researchers think Crohn’s disease with transmural inflammation may be a precursor of malignant peritoneal mesothelioma. Crohn’s disease is a chronic inflammatory condition that affects
There are three ways to treat mesothelioma in a clinic setting — surgery, chemotherapy and radiation. They can be used as standalone therapies or in combination. But those three are basically the only choices. For the moment, at least. Scientists around the world have been busy developing and testing what are called novel molecular therapies for
Another potential target for treating mesothelioma has been identified. It’s the plasma membrane receptor P2X7R. A team of researchers from the University of Ferrara in Italy are reporting that it may be possible to stop mesothelioma by blocking P2X7R. In the online edition of the journal Oncotarget, the researchers said they found P2X7R receptors present
Elderly patients sometimes hear about the benefits of mesothelioma surgery and then ignore it. They think surgery isn’t for them because they’re old to go under the knife. Or they think an operation would be pointless at their advanced age. Or they fear their bodies are too frail to bear up under the physical demands
One of the first things you want to know when you’re diagnosed with mesothelioma is the prognosis — what to expect in the fight to come. The problem is that mesothelioma is a treacherous cancer. So much so that the course it will run can be difficult to predict. Researchers around the world have been studying
One way you can be personally identified is by your handwriting. Malignant pleural mesothelioma can be identified in a somewhat similar way. It has a “signature” of its own. The signature is actually certain biological traits and behaviors that are often identified with this disease. “Biomarkers” is the term used by mesothelioma doctors and researchers.
You undergo mesothelioma surgery with the expectation of living longer. Indeed, that’s the outcome many mesothelioma surgery patients enjoy. But some mesothelioma surgery patients don’t survive as far into the future as they’d hoped. Two of the reasons for this were identified recently by researchers from Italy. First reason: a post-surgical infection develops. Second reason:
